

## Revealing the Potency of 1,3,5-Trisubstituted Pyrazoline as Antimalaria through Combination of *in silico* Studies

(Mendedahkan Potensi Pirazolin 1,3,5-Tritertukarganti sebagai Antimalaria melalui Gabungan Kajian *in silico*)

HERLINA RASYID<sup>1,\*</sup>, NUNUK HARIANI SOEKAMTO<sup>1</sup>, SYADZA FIRDAUSIAH<sup>1,2</sup>, RISKHA MARDIYANTI<sup>1</sup>, BAHRUN<sup>1</sup>, SISWANTO<sup>3</sup>, MUHAMMAD ASWAD<sup>4</sup>, WAHYU DITA SAPUTRI<sup>5</sup>, ARTANIA A. T. SUMA<sup>6</sup>, NUR HILAL SYAHRIR<sup>7</sup> & RISNITA VICKY LISTYARINI<sup>8,9</sup>

<sup>1</sup>Chemistry Department, Faculty of Mathematics and Natural Sciences, Hasanuddin University, Makassar, South Sulawesi 90245, Indonesia

<sup>2</sup>Nano Life Science Institute, Graduate School of Frontier Science Initiative, Kanazawa University, Japan

<sup>3</sup>Department of Statistics, Hasanuddin University, Makassar, South Sulawesi 90245, Indonesia

<sup>4</sup>Faculty of Pharmacy, Hasanuddin University, Makassar, South Sulawesi 90245, Indonesia

<sup>5</sup>Research Center for Quantum Physics, National Research and Innovation Agency (BRIN), Habibie Science and Technology Complex (Puspiptek), Serpong 15314, South Tangerang, Indonesia

<sup>6</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Bulaksumur, Yogyakarta, 55281, Indonesia

<sup>7</sup>Department of Statistics, Faculty of Mathematics and Natural Sciences, Universitas Sulawesi Barat, Majene, 90311, Indonesia

<sup>8</sup>Theoretical Chemistry Division, Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innrain 80-82A, A-6020 Innsbruck, Austria

<sup>9</sup>Chemistry Education Study Program, Sanata Dharma University, Yogyakarta 55282, Indonesia

Received: 31 May 2023/Accepted: 14 September 2023

### ABSTRACT

The potency of 1,3,5-trisubstituted pyrazoline as an antimalarial agent has been studied through quantitative structure-activity relationship, molecular docking, and molecular dynamics simulation as a combination of *in silico* studies. The study commenced by applying quantitative structure-activity relationship (QSAR) to 25 derivative compounds using 3D-descriptor. The genetic algorithm and multiple linear regression analysis were used to construct the QSAR model, which resulting an equation that has  $R_{\text{training}}$  as 0.8100 and  $R_{\text{test set}}$  as 0.9222. Descriptors involved in the QSAR equation are TDB4 m, TDB8s, RDF30e, and RDF552, all of which belong to the group of 3D autocorrelation and RDF. This result is in line with the principal component analysis, which shows that both group descriptors represent whole 3D descriptors. Molecular docking analysis is conducted to study the interaction between pyrazoline derivatives and the falcipain-2 enzyme. Interactions between compound **14** and falcipain-2 is describing by hydrogen bond against Glu14 amino acid residue, more pi-stacking interaction, and van der Waals. Chloroquine as a positive control also presented one hydrogen bond with Gly83, pi-sulfur against Cys42, and van der Waals. The stability of the ligand-enzyme interaction is evaluated by molecular dynamics simulation, and after 100 ns simulations, the root mean square deviation results show that compound **14** and chloroquine have a stable interaction with the falcipain-2 enzyme. Overall, this research provides the insight of 1,3,5-trisubstitued pyrazoline compounds as antimalaria by giving a QSAR equation and used to design a better falcipain-2 inhibitors.

Keywords: Antimalaria; molecular docking; molecular dynamics simulation; QSAR; 1,3,5-trisubstituted pyrazoline

### ABSTRAK

Potensi pirazolin 1,3,5-tritertukarganti sebagai agen antimalaria telah dikaji melalui hubungan struktur-aktiviti kuantitatif, dok molekul dan simulasi dinamik molekul sebagai gabungan kajian *in silico*. Kajian dimulakan dengan menggunakan hubungan struktur-aktiviti kuantitatif (QSAR) kepada 25 sebatian terbitan menggunakan petunjuk 3D.

Algoritma genetik dan analisis linear berbilang telah digunakan untuk membina model QSAR yang menghasilkan persamaan yang mempunyai  $R_{\text{training}}$  sebagai 0.8100 dan  $R_{\text{test set}}$  sebagai 0.9222. Petunjuk yang terlibat dalam persamaan QSAR ialah TDB4 m, TDB8s, RDF30e dan RDF552 yang kesemuanya tergolong dalam kumpulan autokorelasi 3D dan RDF. Keputusan ini adalah selaras dengan analisis komponen utama yang menunjukkan bahawa kedua-dua petunjuk kumpulan mewakili keseluruhan petunjuk 3D. Analisis dok molekul dijalankan untuk mengkaji interaksi antara terbitan pirazolin dan enzim falcipain-2. Interaksi antara sebatian **14** dan falcipain-2 diterangkan dengan ikatan hidrogen terhadap residu asid amino Glu14, lebih banyak interaksi susun pi dan van der Waals. Klorokuin sebagai kawalan positif juga membentangkan suatu ikatan hidrogen dengan Gly83, pi-sulfur terhadap Cys42 dan van der Waals. Kestabilan interaksi ligan-enzim dinilai oleh simulasi dinamik molekul dan selepas simulasi 100 ns, hasil sisihan kuasa dua punca purata menunjukkan bahawa sebatian **14** dan klorokuin mempunyai interaksi yang stabil dengan enzim falcipain-2. Secara keseluruhannya, penyelidikan ini memberikan gambaran tentang sebatian pirazolin 1,3,5-tritertukarganti sebagai antimalaria dengan memberikan persamaan QSAR dan digunakan untuk mereka bentuk perencat falcipain-2 yang lebih baik.

Kata kunci: Antimalaria; dok molekul; QSAR; pirazolina 1,3,5-tritertukarganti; simulasi dinamik molekul

## INTRODUCTION

Malaria is a disease caused by infection with a parasite transmitted by Anopheles mosquitoes and can cause death (Latifah, Subarnas & Chaerunnisaa 2020). This disease is commonly found in tropical and subtropical regions (Ugwu et al. 2020), such as Saharan Africa, Asia, and Latin America (Gogoi et al. 2020). Prevention and treatment of malaria are carried out in various ways, such as terminating the mosquito breeding cycle with insecticides, using mosquito nets and repellents, and using antimalarial drugs for those who are infected by the disease. However, malaria parasites have developed resistance to almost all antimalarial drugs on the market, such as chloroquine (White 2004) and its derivatives (quinine, amodiaquine, primaquine, mefloquine, and halofantrine), as well as other drugs such as antifolate compounds (pyrimethamine, proguanil, and dapsone), and hydroxy-1,4-naphthoquinone (Winstanley 2001), which has caused this disease to become a major global health problem. This encourages researchers and scientists to continue to look for alternative treatments to overcome the problem of resistance (Gogoi et al. 2020).

One of the antimalarial drug candidates currently being looked at and developed by researchers is pyrazoline and its derivatives (Wanare et al. 2010). Pyrazole is a promising antimalarial drug candidate (Himangini et al. 2018), which primarily inhibits hemozoin (Pandey et al. 2016). Pyrazole-pyrazoline substituted with benzene sulphonamide is active against chloroquine-sensitive (3D7) and CQ-resistant (RKL-9) strains of *Plasmodium falciparum* with an  $EC_{50}$  value of 2  $\mu\text{M}$  (Himangini et al. 2018). Several compounds of oxazoline-pyrazoline

hybrids were successfully synthesized by Pandey et al. (2016) through the condensation reaction of substituted oxazoline-based chalcones (3a-m) and substituted hydrazine in methanol, exhibiting promising *in vitro* antimalarial activity for chloroquine-sensitive CQS (3D7) and chloroquine-resistant CQR (RKL9) strains. One of the pyrazoline compounds ( $IC_{50}$  0.322 mg/mL) exhibited significant *in vivo* antimalarial potential against a *Plasmodium berghei* mouse model with a 4i-hematin (1:1 stoichiometry) complex, which suggests that heme may be one possible target for these hybrid compounds.

Another type of pyrazole currently being developed as an antimalarial drug is 1,3,5-trisubstituted pyrazoline. This compound can be synthesized by the reflux method using the precursor chalcones and nicotinic acid hydrazide in methanol (Mishra et al. 2017). Research on 1,3,5-trisubstituted pyrazoline compounds *in vitro* carried out on *P. falciparum* strains that were sensitive to chloroquine (MRC-02) and resistant to chloroquine (RKL9) at nanomolar concentrations showed activity inhibiting the formation of  $\beta$ -hematin (BHIA50). The antimalarial mechanism of this compound is the same as that of chloroquine, which involves inhibition of the formation of hemozoin. *In vivo*, some of these compounds showed better antimalarial activity against resistant *P. falciparum* strains than chloroquine (Acharya et al. 2010). This finding showed the potential of pyrazoline derivative as a candidate of antimalarial drug. In 2006, Chimenti et al. studied the potential of 1,3,5-trisubstituted pyrazoline as highly selective monoamine oxidase inhibitor by using 3D-QSAR analysis. The other study conducted by George et al. (2020) synthesized some of

1,3,5-trisubstituted pyrazoline as a breast cancer and did molecular docking as their *in silico* study and resulted that the synthesized compound had a better docking score than erlotinib as positive control. Recently, QSAR analysis on tri-substituted pyrazolines was conducted to evaluate their potential as phosphodiesterase 5 (PDE5) (Nandi et al. 2021). However, *in silico* analysis of 1,3,5-trisubstituted pyrazoline especially Quantitative Structure Activity Relationship (QSAR) as antimalarial had never been conducted.

Currently, recent developments in drug design use *in silico* analysis before *in vitro* or *in vivo* stages. The process of finding candidate antimalarial drug compounds can be carried out either *in vitro*, *in vivo* or *in silico* (Gemma et al. 2007). The use of *in silico* methods can be computerized with the principle of allocating a variety of complex structures and mechanisms for predicting or investigating biological activity (Pornputtpong et al. 2020) The *in silico* method is a solution to the high demand for medicinal compounds and conventional research processes, which are expensive and take a long time (Mandal, Moudgil & Mandal 2009). Quantitative Structure-Activity Relationship (QSAR) is a computational method in predicting the relation between compound structure and their activity as a mathematic equation. This method could be used to design a new and better activity of a compound (Rasyid et al. 2023). The recent QSAR development is attempting the 3D descriptor to construct the equation (Banjare et al. 2023). QSAR analysis combine with molecular docking analysis gave a better insight about relation of structure-activity and mechanism of action from a bioactive compound (Laskar, Mazumder & Talukdar 2023).

The 1,3,5-trisubstituted pyrazoline compounds was docked into the active site of falcipain-2 enzyme. This enzyme has a role in the parasite's life cycle by involving in the hydrolysis of hemoglobin. This enzyme catalyzed the change of hemoglobin to be hemozoin. This change was needed to produce cell's food. The inhibition of the enzyme caused swelling and resulted in disrupted food manufacture. Then, the cell died caused by starvation (Himangini et al. 2018).

In this research, we conducted a combination of *in silico* studies through QSAR, molecular docking, and molecular dynamics simulation. This method gave an insight on designing a better bioactive compound through QSAR analysis, continued with molecular docking and molecular dynamics simulation to know the binding affinity and the stability of 1,3,5-trisubstituted pyrazoline against falcipain-2 enzyme.

## MATERIALS AND METHODS

### DATA COLLECTION AND GEOMETRY OPTIMIZATION

A total of 25 derivative compounds of 1,3,5-trisubstituted pyrazoline were collected from two references shown in Figure 1 as the core structure of 1,3,5-trisubstituted pyrazoline and Table 1 which show their derivative compounds (Acharya et al. 2010; Mishra et al. 2017).

All compounds were tested as antimalaria agents against chloroquine-sensitive (MRC-02) strains. Those compounds were modeled and optimized using the DFT B3LYP 6-311G (d,p) method in the ORCA program (Nesse et al. 2012) and visualized using Avogadro software (Hanwell et al. 2012).

### 3D-DESCRIPTOR CALCULATION

The optimized structures of 1,3,5-trisubstituted pyrazoline were then subjected to calculation of the 3D-descriptors using the PaDEL descriptor resulting in 431 descriptors, which were used for further analysis using principal component analysis (PCA) and QSAR equation development (Yap 2011).

### PRINCIPLE COMPONENT ANALYSIS (PCA)

To examine the distribution of 431 descriptors on 25 compounds, PCA was carried out with RStudio software using the FactoMineR package (Le, Josse & Husson 2008). Normalization of the data was conducted first to overcome the magnitude of variance and scale differences between descriptors. Two-dimension visualization was carried out using the factextra package (Kassambara & Mundt 2016).

### QSAR MODEL DEVELOPMENT AND VALIDATION

QSAR model development was started by normalizing the data and performing pre-treatment to ensure the development of a good QSAR model using software from the Drug Theoretics and Cheminformatics Laboratory (dtclab.web.com). The 431 descriptors from each compound were divided into two parts: the training set and the test set. The training set was used to develop the QSAR equation, and the test set was used to validate the QSAR model. The training set data was further analyzed using the BuildQSAR software (De Oliveira & Gaudio 2000) by applying a genetic algorithm and multilinear regression (Hemmateenejad et al. 2003). Three models were selected for further validation.

Validation of the QSAR model was done for internal and external validations. Internal validation included  $R^2_{\text{training}}$ ,  $Q^2$ , and  $Y_{\text{randomization}}$  and external validation included the  $R^2_{\text{test set}}$ ,  $r^2_m$ , and leverage approach.




FIGURE 1. Core structure of 1,3,5-trisubstituted pyrazoline compound

TABLE 1. Structure and bioactivity value of 1,3,5-trisubstituted pyrazoline derivative compounds

Compound code	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	R <sub>6</sub>	IC <sub>50</sub> (μm)	References
1	C <sub>2</sub> H <sub>5</sub>	H	H	H	H	0.0810	
2	i-C <sub>3</sub> H <sub>7</sub>	H	H	H	H	0.1100	
3	CH <sub>3</sub>	H	CH <sub>3</sub>	H	CH <sub>3</sub>	0.0940	
4	OCH <sub>3</sub>	H	H	OCH <sub>3</sub>	H	0.0400	
5	H	OCH <sub>3</sub>	OCH <sub>3</sub>	H	H	0.0300	
6	H	H	OCH <sub>2</sub> CH <sub>3</sub>	H	H	0.2140	
7	H	CH <sub>3</sub>	OCH <sub>3</sub>	H	H	0.0630	
8	H	H	Br	H	H	0.1410	(Mishra et al. 2017)
9	H	H	F	H	H	2.5000	
10	H	H	NO <sub>2</sub>	H	H	1.5660	
11	H	H	OCH <sub>3</sub>	H	H	0.0590	
12	H	Cl	H	H	H	0.2400	
13	H	H	i-C <sub>3</sub> H <sub>7</sub>	H	H	0.0340	
14	H	H	C <sub>3</sub> H <sub>7</sub>	H	H	0.0220	
15	H	H	Oi-C <sub>3</sub> H <sub>7</sub>	H	H	0.0380	
16	Cl	H	Cl	H	H	0.0375	
17	H	H	H	H	H	0.0304	
18	CH <sub>3</sub>	H	H	H	H	0.0625	
19	H	H	CH <sub>3</sub>	H	H	0.0555	
20	H	OCH <sub>2</sub> CH <sub>3</sub>	OCH <sub>3</sub>	H	H	0.0755	(Acharya et al. 2010)
21	Br	H	H	H	H	0.0272	
22	H	OCH <sub>3</sub>	OCH <sub>3</sub>	OCH <sub>3</sub>	H	0.0265	
23	OCH <sub>3</sub>	H	H	Br	H	0.0495	
24	H	Br	H	H	H	0.0260	
25	H	NO <sub>2</sub>	H	H	H	0.1065	

#### MOLECULAR DOCKING ANALYSIS

To evaluate the inhibition mechanism, molecular docking was attempted on the complex of falcipain-2 enzyme (PDB ID: 3BPF) (Himangini et al. 2018). Determination of the docked compound was based on the drug likeness evaluation using Lipinski rules. All compounds were analyzed for their ADME properties using SWISSADME web program ([www.swissadme.ch](http://www.swissadme.ch)). The selected compound was compound 14 due to good ADME results and has the lowest  $IC_{50}$  value. The positive control was chloroquine. The docking stage was started in the Chimera software to prepare the protein and ligand structures using *Dockprep* tools. Docking protocols were set in the box grid size of  $50 \times 50 \times 50 \text{ \AA}$ , with a spacing of  $0.375 \text{ \AA}$  in the AutoDock 4 and AutoDock Tools programs (Morris et al. 2009). The Lamarckian algorithm was used and set to produce 10 conformations. The visualization of the conformation was done in the Discovery Studio Visualizer (Dassault Systèmes 2019).

#### MOLECULAR DYNAMICS SIMULATION PROTOCOLS

The complex stability of the best conformation result in the molecular docking stage was further analyzed using molecular dynamics simulation in the YASARA

Structure software (YASARA Bioscience GmbH, Vienna, Austria) (Land & Humble 2018). The force field used is Amber14 in the periodic boundary condition (Wang et al. 2004). The complex was set at a temperature of 310 K and a pH of 7.4. TIP3P solvent (Mark & Nilsson 2001) and counterions ( $Na^+$ ,  $Cl^-$ ) were added to neutralize the system. Then, the system was run for 100 ns at a timestep of 0.25 fs. Trajectory data was collected every 25 ps and used to analyze the root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the radius of gyration.

#### RESULTS AND DISCUSSION

##### PRINCIPLE COMPONENT ANALYSIS (PCA)

PCA is performed by grouping the descriptors according to their categories. By using two main components, we describe the descriptor (Figure 2). The description of the descriptor can be seen by using two main components with a total variance of 87.5%, which suggests that two PCA variables have represented 87.5% of the 25 compounds. It is clear that several of the descriptors overlap. The charged partial surface area and WHIM descriptor groups have similar areas. These descriptors




FIGURE 2. PCA result analysis of the 3D descriptors of 1,3,5-trisubstituted pyrazoline



have identical values and are correlated among the 25 substances. Moreover, several descriptors overlap with one another. For instance, the gravitational index descriptor overlaps with seven other descriptor groups. This demonstrates that the properties of the gravitational descriptors must not be linked with one another according to the linear regression assumptions. This description demonstrates the need for more descriptor screening to produce appropriate linear regression model results.

Even though practically all descriptor groups are mutually exclusive, two are not, namely the 3D autocorrelation group and the RDF group. These two groups tend to measure different elements but can reflect practically all of the existing descriptors. As a result, the descriptors in these two groups have the potential to be selected as the variable selection stage in the regression model.

#### DEVELOPMENT OF THE QSAR MODEL

Data division was conducted using the Kennard–Stone algorithm (Kennard & Stone 1969), which resulted in 80% training set data, and the remaining test set data. The development of the QSAR model was carried out several times, and three QSAR models with R values of >0.8 were selected. Table 2 shows the selected QSAR model,

which was validated and chosen to be the best QSAR model. Validation of the QSAR model through internal validation was done using several statistical parameters, such as least squares fit ( $R^2$ ), cross-validation ( $Q^2$ ), and bootstrapping and scrambling (Y-randomization).

There are some of minimum standard parameters to produce good QSAR models such as square correlation coefficient ( $R^2$ ) should be bigger than 0.6 as well as the R value greater equals to 0.8. The difference of  $R^2$  and  $Q^2$  should be less than 0.3 to give a good predictability. Value of  $R^2$  and  $Q^2$  from randomization stage should lower than the real  $R^2$  and  $Q^2$  (Veerasamy et al. 2011).

Based on the minimum standard, all QSAR models fulfill the minimum parameters of R and  $R^2$ , but only Model 2 and Model 3 have a difference of  $R^2$  and  $Q^2$  lower than 0.3. The results of the Y-randomization test are shown in Table 3. Randomization was done five times and showed that only Model 2 gave an  $R^2$  and  $Q^2$  value lower than the original value. By this internal validation, Model 2 is the better QSAR model, but an external validation is still needed.

The statistical external validation parameters used in this study are the  $R^2_{\text{test set}}$  and  $r_m^2$ . A good model is generated if the  $R^2_{\text{test set}}$  value is >0.6 or if the  $r_m^2$  value is >0.5. The external validation result showed that all models fulfilled the statistical parameters, but Model 2 presented the greatest  $r_m^2$  value.

TABLE 2. QSAR models from the BuildQSAR program

No	Parameters	Model 1	Model 2	Model 3
1	Descriptors	TDB4 m, MOMI-X, RDF90u, RDF70s	TDB8 m, TDB8s, RDF30e, RDF55e	TDB8u, TDB10s, RDF55e, Te
2	$N_{\text{int,training set}}$	20	20	20
3	R	0.8100	0.8100	0.8360
4	p	0.002	0.002	0.001
5	$Q^2$	0.324	0.384	0.449
6	$R^2-Q^2$	0.3321	0.2721	0.2499
7	SPress	0.410	0.496	0.465
8	SDEP	0.364	0.441	0.413
9	$R_{\text{test set}}$	0.9743	0.9222	0.9056
10	$R^2_{\text{test set}}$	0.9492	0.8505	0.8204
11	$r_m^2$	0.4269	0.5352	0.5197

TABLE 3. Y-randomization results of each original models

Model	Y-randomization test Model 1					Y-randomization test Model 2					Y-randomization test Model 3				
	R	R <sup>2</sup>	Q <sup>2</sup>	Model	R	R <sup>2</sup>	Q <sup>2</sup>	Model	R	R <sup>2</sup>	Q <sup>2</sup>	Model	R	R <sup>2</sup>	Q <sup>2</sup>
Original	0.8100	0.6555	0.3245	Original	0.8100	0.6561	0.3837	Original	0.8360	0.6989	0.4487				
Random 1	0.7680	0.5898	0.2970	Random 1	0.6980	0.4872	0.2180	Random 1	0.6830	0.4665	0.0210				
Random 2	0.7600	0.5776	0.1450	Random 2	0.6590	0.4343	n.p	Random 2	0.7180	0.5155	0.0120				
Random 3	0.7100	0.5041	0.1630	Random 3	0.6570	0.4316	n.p	Random 3	0.7310	0.5344	0.3480				
Random 4	0.8910	0.7939	0.6820	Random 4	0.6410	0.4109	n.p	Random 4	0.7040	0.4956	n.p				
Random 5	0.8860	0.7850	0.6660	Random 5	0.6990	0.4886	0.1620	Random 3	0.8220	0.6757	0.3640				

Due to the internal and external validation results, Model 2 was chosen as the best QSAR model. The QSAR equation is:  
 $\text{Log IC}_{50} = -0.4883 \times \text{TDB4 m} + 4.2103 \times \text{TDB8s} + 1.4521 \times \text{RDF30c} - 3.3199$   
 $\times \text{RDF55e} - 2.3872$

The descriptors involved in the QSAR model are TDB8 m, TDB8s, RDF30e, and RDF55e. The four descriptors come from two groups of descriptors, namely 3D autocorrelation and RDF. These results are appropriate with PCA, which shows that both descriptor groups represent the other descriptor.

Nowadays, QSAR analysis towards pyrazoline derivatives has been conducted for several activities. Hammoudan and Chafi (2023) have conducted a QSAR analysis of pyrazoline derivatives as carbonic anhydrase inhibitors. Through internal and external validation, the QSAR model resulted has higher  $R^2$ ,  $R^2_{\text{test}}$  and  $Q^2_{\text{cv}}$  values ( $R^2 = 0.79$ ,  $R^2_{\text{test}} = 0.95$ ,  $Q^2_{\text{cv}} = 0.64$ ). The others QSAR analysis also attempted as inhibitors of Mycobacterium tuberculosis strain H37Rv by Venkatesan et al. (2023). The model resulted by using combination of machine learning in Python program language and found that

the model score has  $R^2$  value of 0.5901. QSAR models resulted for several bioactivity could be useful to design more active compounds of pyrazoline.

#### MOLECULAR DOCKING ANALYSIS

Molecular docking analysis was conducted on the complex 1,3,5-trisubstituted pyrazoline and the positive control (chloroquine) against falcipain-2 enzyme. Drug likeness analysis was conducted before the docking stage to select one of derivative compounds to be use as ligand in molecular docking. Table 4 shows the result of drug likeness analysis through SWISSADME program and found that all compounds meet the Lipinski rules indicating that they have good ADME profile when use as a drug. Compound **14** was selected as ligand to be docked with falcipain-2 enzyme because its lowest  $IC_{50}$  value comparing with the others molecule.

TABLE 4. Drug likeness prediction result using Lipinski rules

Compounds Code	Lipinski Rules			Log P	Druglikeness (Yes/No)
	Molecular Weight	Num. H-bond Acceptor	Num. H-bond Donor		
<b>1</b>	371.43	4	1	2.94	Yes
<b>2</b>	385.46	4	1	3.15	Yes
<b>3</b>	385.46	4	1	3.15	Yes
<b>4</b>	403.43	6	1	1.86	Yes
<b>5</b>	403.43	6	1	1.86	Yes
<b>6</b>	449.50	5	1	3.21	Yes
<b>7</b>	387.43	5	1	2.39	Yes
<b>8</b>	422.27	4	1	3.10	Yes
<b>9</b>	361.37	5	1	2.88	Yes
<b>10</b>	388.38	6	1	1.52	Yes
<b>11</b>	373.40	5	1	2.18	Yes
<b>12</b>	377.82	4	1	2.99	Yes
<b>13</b>	385.46	4	1	3.15	Yes
<b>14</b>	385.46	4	1	3.15	Yes
<b>15</b>	401.46	5	1	2.60	Yes
<b>16</b>	412.27	4	1	3.47	Yes
<b>17</b>	343.38	4	1	2.50	Yes
<b>18</b>	357.41	4	1	2.72	Yes
<b>19</b>	357.41	4	1	2.72	Yes
<b>20</b>	417.46	6	1	2.07	Yes
<b>21</b>	422.27	4	1	3.10	Yes
<b>22</b>	433.46	7	1	1.28	Yes
<b>23</b>	452.30	5	1	2.77	Yes
<b>24</b>	422.27	4	1	3.10	Yes
<b>25</b>	388.38	6	1	1.52	Yes



The ligands were docked into the active site of the falcipain-2 enzyme (PDB ID:3BPF). Molecular docking analysis showed binding energy and the interaction between ligands and the enzyme. Compound **14** has a lower binding energy of about  $-7.84$  kcal/mol than chloroquine, which has  $-7.11$  kcal/mol. The lower binding energy is due to the stronger interaction between ligands and the enzyme. Figure 3 shows the interaction between both ligands and falcipain-2. Ligand **14** has one hydrogen bond against the Glu14 amino acid residue, more pi-stacking interactions, and van der Waals. Chloroquine also presented one hydrogen bond with Gly83, pi-sulfur against Cys42, and van der Waals. Both ligands showed similar amino acid interactions with the cocrystal ligands of the falcipain-2 and epoxysuccinate complex.

Epoxysuccinate and the inhibitor falcipain-2 have four hydrogen bonds against three amino acid residues: Gly83, Gln36, and His174 (Himangini et al. 2018). The similar interaction showed that both ligands have occupied the catalytic site of the enzyme and indicated the potential activity as falcipain-2 inhibitor.

#### MOLECULAR DYNAMICS SIMULATION

A molecular dynamic simulation has been conducted with a 100 ns simulation time. These simulations are dedicated to the complex of ligand **14** and chloroquine as a positive control. Those ligands were docked into the active site of the falcipain-2 enzyme, and they were chosen due to their binding energy, which is lower than the other tested ligand in molecular docking analysis.




FIGURE 3. 2D-interactions of (a) compound **14** and (b) chloroquine against falcipain-2 enzyme

The radius of gyration is a parameter that describes the equilibrium conformation of a whole system. The lowest value showed the folded condition of the protein structure, and the highest value described the unfolded structure. We can see in Figure 4 that both ligands do not contribute to the folding effect of the protein complex.

This data is also confirmed in the RMSD graph (Figure 5). The RMSD analysis showed that both ligands

provide stability to the protein. The high RMSD value is due to the protein structure, which has a high RMSD from the start. This is due to the low stability of the protein structure. Meanwhile, in Figure 6, the RMSF results showed that the positive control ligand (CHL) has better stability than ligand 14. However, the two ligands show the same fluctuation pattern, indicating that the two ligands do not have a folding effect on the protein structure.




FIGURE 4. Radius of gyration plot between ligands and falcipain-2 enzyme




FIGURE 5. Root mean square deviation (RMSD) plot between ligands and falcipain-2 enzyme




FIGURE 6. Root mean square deviation (RMSD) plot between ligands and falcipain-2 enzyme

### CONCLUSIONS

A combination of *in silico* studies have been conducted on the 1,3,5-trisubstituted pyrazoline derivative compounds. A total of 25 compounds were used to construct the validated QSAR equation. Descriptors involved in the QSAR equation are TDB8m, TDB8s, RDF30e, and RDF55e, all of which belong to the 3D autocorrelation and RDF groups of descriptors. The molecular docking analysis of compound **14** against the falcipain-2 enzyme showed a lower binding energy than chloroquine as the positive control. To evaluate the stability of the enzyme–ligand complexes, molecular dynamics simulation was performed and showed that the addition of ligands could reduce the RMSD of single protein, indicating the potency of the ligand as an inhibitor of the falcipain-2 enzyme. Furthermore, the QSAR equation resulted could be utilized to design new compounds with remarkable activity and continued with synthesized stage as well as tested *in vitro* and *in vivo* stage.

### ACKNOWLEDGEMENTS

The authors thank the Institute for Research and Community Service, Hasanuddin University, for the research grant (No. 00323/UN4.22/PT.01.03/2023) in the scheme of Fundamental Collaborative Research in 2023.

### REFERENCES

- Acharya, B.N., Saraswat, D., Tiwari, M., Shrivastava, A.K., Ghorpade, R., Bapna, S. & Kaushik, M.P. 2010. Synthesis and antimalarial evaluation of 1,3,5-trisubstituted pyrazolines. *European Journal of Medicinal Chemistry* 45: 430-438.
- Banjare, L., Singh, Y., Verma, S.K., Singh, A.K., Kumar, P., Kumar, S., Jain, A.K. & Thareja, S. 2023. Multifaceted 3D-QSAR analysis for the identification of pharmacophoric features of biphenyl analogues as aromatase inhibitors. *Journal of Biomolecular Structure and Dynamics* 41(4): 1322-1341.
- BIOVIA. 2019. *Discovery Studio Visualizer*, Dassault Systèmes, San Diego.
- Chimentri, F., Bolasco, A., Manna, F., Secci, D., Chimenti, P., Granese, A., Befani, O., Turini, P., Cirilli, R., La Torre, F., Alcaro, S., Ortuso, F. & Langer, T. 2006. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-Trisubstituted-4,5-Dihydro-(1*H*)-pyrazole derivatives as potent and highly selective monoamine oxidase a inhibitors. *Current Medicinal Chemistry* 13: 1411-1428.
- De Oliveira, D.B. & Gaudio, A.C. 2000. BuildQSAR: A new computer program for QSAR analysis. *Quant. Struct.-Act. Relat.* 19: 599-601.
- Gemma, S., Campiani, G., Butini, S., Kukreja, G., Joshi, B.P., Persico, M., Catalanotti, B., Novellino, E., Fattorusso, E., Nacci, V., Savini, L., Taramelli, D., Basilico, N., Morace, G., Yardley, V. & Fattorusso, C. 2007. Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: Exploring an innovative pharmacophore. *J. Med. Chem.* 50: 595-598.

- George, R.F., Kandeel, M., El-Ansary, D.Y. & El Kerdawy, A.M. 2020. Some 1,3,5-trisubstituted pyrazoline derivatives targeting breast cancer: Design, synthesis, cytotoxic activity, EGFR inhibition and molecular docking. *Bioorg. Chem.* 99: 103780.
- Gogoi, P., Shakya, A., Ghosh, S.K., Gogoi, N., Gahtori, P., Singh, N., Bhattacharyya, D.R., Singh, U.P. & Bhat, H.R. 2020. *In silico* study, synthesis, and evaluation of the antimalarial activity of hybrid dimethoxy pyrazole 1,3,5-triazine derivatives. *Journal of Biochemical and Molecular Toxicology* 35(3): e22682.
- Hammoudan, I. & Chafi, M. 2023. QSAR modelling of pyrazoline derivative as carbonic anhydrase inhibitors. *Environ Sci Pollut Res.* <https://doi.org/10.1007/s11356-023-28277-3>
- Hanwell, M.D., Curtis, D.E., Loni, D.C., Vandermeersch, T., Zurek, E. & Hutchison, G.R. 2012. Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. *Journal of Cheminformatics* 4(17): 1-17.
- Hemmateenejad, B., Akhond, M., Miri, R. & Shamsipur, M. 2003. Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: Application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogues). *Journal of Chemical Information and Computer Sciences* 43(4): 1328-1334.
- Himangini, Pathak, D.P., Sharma, V. & Kumar, S. 2018. Designing novel inhibitors against falcipain-2 of *Plasmodium falciparum*. *Bioorganic & Medicinal Chemistry Letters* 28: 1566-1569.
- Kassambara, A. & Mundt, F. 2017. *Package 'Factoextra', Extract and Visualize the Result of Multivariate Analyses.* <https://cran.r-project.org/web/packages/factoextra/index.html>
- Kennard, R.W. & Stone, L.A., Feb. 1969. Computer aided design of experiments. *Technometrics* 11(1): 137-148.
- Land, H. & Humble, M.S. 2018. YASARA: A tool to obtain structural guidance in biocatalytic investigations. *Methods Mol. Biol.* 1685: 43-67.
- Laskar, Y.B., Mazumder, P.B. & Talukdar, A.D. 2023. *Hibiscus sabdariffa* anthocyanins are potential modulators of estrogen receptor alpha activity with favourable toxicology: A computational analysis using molecular docking, ADME/Tox prediction, 2D/3D QSAR and molecular dynamics simulation. *Journal of Biomolecular Structure and Dynamics* 41(2): 611-633.
- Latifah, N., Subarnas, A. & Chaerunnisaa, A.Y. 2020. Antimalaria medicine and its mechanism: A review. *Majalah Farmasetika* 5(1): 39-48.
- Le, S., Josse, J. & Husson, F. 2008. FactoMineR: An R package for multivariate analysis. *Journal of Statistical Software* 25(1): 1-18.
- Mandal, S., Moudgil, M. & Mandal, S.K. 2009. Rational drug design. *European Journal of Pharmacology* 625: 90-100.
- Mark, P. & Nilsson, L. 2001. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K. *J. Phys. Chem. A* 105(43): 9954-9960.
- Mishra, V.K., Mishra, M., Kashaw, V. & Kashaw, S.K. 2017. Synthesis of 1,3,5-trisubstituted pyrazolines as potential antimalarial and antimicrobial agents. *Bioorganic & Medicinal Chemistry* 25(6): 1949-1962.
- Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S. & Olson, A.J. 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.* 30(16): 2785-2791.
- Nandi, S., Kumar, P., Amin, S.A., Jha, T. & Gayen, S. 2021. First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis. *SAR and QSAR in Environmental Research* 32(11): 917-939.
- Neese, F., Wennmohs, F., Becker, U. & Riplinger, C. 2020. The ORCA quantum chemistry program package. *The Journal of Chemical Physics* 152(22): 224108.
- Pandey, A.K., Sharma, S., Pandey, M., Alam, M.M., Shaquiquzzaman, M. & Akhter, M. 2016. 4,5-Dihydrooxazole-pyrazoline hybrids: Synthesis and their evaluation as potential antimalarial agents. *European Journal of Medicinal Chemistry* 123: 476-486.
- Pornputtapong, N., Suriyapakorn, B., Satayamapakorn, A., Larpadisorn, K., Janviriyakul, P. & Khemawoot, P. 2020. *In silico* analysis for factors affecting anti-malarial penetration into red blood cells. *Malaria Journal.* 19: 215.
- Rasyid, H., Soekamto, N.H., Seniwati, Firdausiah, S. & Firdaus. 2023. Modelling the anticancer activity of 4-alkoxy cinnamic analogues using 3D-descriptors and genetic algorithm-multiple linear regression (GA-MLR) method. *Journal of King Saud University – Science* 35(3): 102514.
- Ugwu, D.I., Ugwu, M.C., Eze, F.U., Eze, C.C., Ugwuja, D.I., Ekoh, O.C. & Ezugwu, J.A. 2020. Design of antimalarial agents: A review. *Journal of Pharmaceutical Research and Therapeutics* 1(1): 09-19.
- Veerasingam, R., Rajak, H., Jain, A., Sivadasan, S., Varghese, C. P. & Agrawal, R. K. 2011. Validation of QSAR Models – Strategies and Importance. *International Journal of Drug Design and Discovery.* 2(3): 5110519
- Venkatesan, J., Prabha, T., Selvaraj, J., Sudeepan, J. & Thangavel, S. 2023. A machine learning language to build a QSAR model of pyrazoline derivative inhibitors targeting *Mycobacterium tuberculosis* strain H37Rv. *Letters in Drug Design & Discovery* 20(2): 167-180.

- Wanare, G., Aher, R., Kawathekar, N., Ranjan, R., Kaushik, N.K. & Sahal, D. 2010. Synthesis of novel  $\alpha$ -pyranochalcones and pyrazoline derivatives as *Plasmodium falciparum* growth inhibitors. *Bioorganic & Medicinal Chemistry Letters* 20: 4675-4678.
- Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A. & Case, D.A. 2004. Development and testing of a general AMBER force field. *J. Comput. Chem.* 25(9): 1157-1174.
- White, N.J. 2004. Antimalarial drug resistance. *The Journal of Clinical Investigation* 113(8): 1084-1092.
- Winstanley, P. 2001. Modern chemotherapeutic options for malaria. *Lancet Infectious Disease* 1: 242-250.
- Yap, C.W. 2011. PaDEL-Descriptor: An open source software to calculate molecular descriptors and fingerprints. *Journal of Computational Chemistry* 32: 1466-1474.

\*Corresponding author; email: herlinarasyid@unhas.ac.id